NASDAQ: BWAYBrainsway Ltd Stock
$5.45-0.15 (-2.68%)
Updated Dec 7, 2023
BWAY Price
$5.45
Fair Value Price
N/A
Market Cap
$90.07M
52 Week Low
$1.38
52 Week High
$6.85
P/E
-11.35x
P/B
2.19x
P/S
2.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.79M
Earnings
-$8.19M
Gross Margin
73.1%
Operating Margin
-32.88%
Profit Margin
-28.5%
Debt to Equity
0.45
Operating Cash Flow
-$3M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BWAY Overview
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BWAY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BWAY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BWAY is good value based on its book value relative to its share price (2.19x), compared to the US Medical Devices industry average (3.55x)
P/B vs Industry Valuation
BWAY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BWAY due diligence checks available for Premium users.
Be the first to know about important BWAY news, forecast changes, insider trades & much more!
BWAY News
Valuation
BWAY fair value
Fair Value of BWAY stock based on Discounted Cash Flow (DCF)
Price
$5.45
Fair Value
$6.98
Undervalued by
21.95%
BWAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BWAY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.35x
Industry
34.08x
Market
31.17x
BWAY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.19x
Industry
3.55x
BWAY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BWAY's financial health
Profit margin
Revenue
$8.3M
Net Income
-$230.0k
Profit Margin
-2.8%
BWAY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BWAY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$59.8M
Liabilities
$18.6M
Debt to equity
0.45
BWAY's short-term assets ($52.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BWAY's short-term assets ($52.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BWAY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BWAY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.4M
Investing
-$506.0k
Financing
-$56.0k
BWAY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BWAY vs Medical Device Stocks
Brainsway Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.